Journal: Journal of Clinical Medicine

Article Title: Intravitreal Dexamethasone Implant Switch after Anti-VEGF Treatment in Patients Affected by Retinal Vein Occlusion: A Review of the Literature

doi: 10.3390/jcm13175006

Figure Lengend Snippet: Illustrative summary of the pathophysiology of retinal vein occlusion, highlighting the molecular targets of the intravitreal treatments. ↑: increase; ↓: decrease.

Article Snippet: In particular, it has been shown that the sustained-release intravitreal 0.7 mg corticosteroid DEX implant (Ozurdex ® , AbbVie Inc., North Chicago, IL, USA) is beneficial in treating RVO [ , ].

Techniques:

Journal: Journal of Clinical Medicine

Article Title: Intravitreal Dexamethasone Implant Switch after Anti-VEGF Treatment in Patients Affected by Retinal Vein Occlusion: A Review of the Literature

doi: 10.3390/jcm13175006

Figure Lengend Snippet: Summary of the studies analyzing the switch from anti-VEGF therapy to DEX implant in RVO.

Article Snippet: In particular, it has been shown that the sustained-release intravitreal 0.7 mg corticosteroid DEX implant (Ozurdex ® , AbbVie Inc., North Chicago, IL, USA) is beneficial in treating RVO [ , ].

Techniques: Clinical Proteomics, Sequencing, Injection, Comparison, Functional Assay, Medications

Journal: Frontiers in Bioengineering and Biotechnology

Article Title: Small molecule-mediated regenerative engineering for craniofacial and dentoalveolar bone

doi: 10.3389/fbioe.2022.1003936

Figure Lengend Snippet: Small molecular agents examined in vivo .

Article Snippet: Dexamethasone , Hydroxysteroids , 392.5 g/mol , 2.18 μg/mg of chi-MSNs , Sprague Dawley rats with skull defects (5 mm in diameter), tools used not reported , Gelfoam implants containing DEX-embedded silica nanoparicles were transplanted to the defect site , Higher bone volume to total volume (BV/TV) ratios; enhanced skull bone regeneration , .

Techniques: In Vivo, Molecular Weight, Produced, Phospho-proteomics, Activation Assay, Expressing, Inhibition, Extraction, Gene Expression, Mutagenesis, Generated, Injection

Journal: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

Article Title: Role of implants in the treatment of diabetic macular edema: focus on the dexamethasone intravitreal implant

doi: 10.2147/DMSO.S73540

Figure Lengend Snippet: Summary of main clinical trials with DEX intravitreal implant for the treatment of diabetic macular edema

Article Snippet: The DEX intravitreal implant (Ozurdex ® ) consists of 0.7 mg of DEX in a NOVADUR ® (Styrolution; Aurora, Illinois USA) solid polymer sustained-release drug-delivery system (DDS).

Techniques: Clinical Proteomics

Journal: Indian Journal of Ophthalmology

Article Title: Comparison between Ozurdex and intravitreal anti-vascular endothelial growth factor treatment for retinal vein occlusion–related macular edema: A systematic review and meta-analysis of randomized controlled trials

doi: 10.4103/ijo.IJO_382_19

Figure Lengend Snippet: The summary of characteristics of included clinical trials

Article Snippet: Novartis’ two studies indicated that anti-VEGF agents significantly reduced the CRT compared with DEX implant at 6 months [weighted mean difference: 158.53 μm, 95% confidence interval (CI): (71.09, 245.96), P = 0.0004].

Techniques:

Journal: Indian Journal of Ophthalmology

Article Title: Comparison between Ozurdex and intravitreal anti-vascular endothelial growth factor treatment for retinal vein occlusion–related macular edema: A systematic review and meta-analysis of randomized controlled trials

doi: 10.4103/ijo.IJO_382_19

Figure Lengend Snippet: A forest plot diagram showing the mean change in BCVA from baseline level in the eyes suffering from RVO-related ME after treatments with anti-VEGF agents and DEX. Follow-up examinations occurred at 1 (a), 2 (b), 3 (c), 4 (d), 5 (e), and 6 months (f) after initiating therapy. Dots represent the estimated mean differences, and error bars indicate 95% CIs. Data are presented as mean [95% CI]. IV, inverse variance

Article Snippet: Novartis’ two studies indicated that anti-VEGF agents significantly reduced the CRT compared with DEX implant at 6 months [weighted mean difference: 158.53 μm, 95% confidence interval (CI): (71.09, 245.96), P = 0.0004].

Techniques:

Journal: Indian Journal of Ophthalmology

Article Title: Comparison between Ozurdex and intravitreal anti-vascular endothelial growth factor treatment for retinal vein occlusion–related macular edema: A systematic review and meta-analysis of randomized controlled trials

doi: 10.4103/ijo.IJO_382_19

Figure Lengend Snippet: A forest plot diagram showing the mean change in CRT from baseline level in the eyes suffering from RVO-related ME after treatments with anti-VEGF agents and DEX. The follow-up examinations occurred at 6 months, the endpoint of clinical trial. Data are presented as mean [95% CI]. IV, inverse variance

Article Snippet: Novartis’ two studies indicated that anti-VEGF agents significantly reduced the CRT compared with DEX implant at 6 months [weighted mean difference: 158.53 μm, 95% confidence interval (CI): (71.09, 245.96), P = 0.0004].

Techniques:

Journal: Indian Journal of Ophthalmology

Article Title: Comparison between Ozurdex and intravitreal anti-vascular endothelial growth factor treatment for retinal vein occlusion–related macular edema: A systematic review and meta-analysis of randomized controlled trials

doi: 10.4103/ijo.IJO_382_19

Figure Lengend Snippet: A forest plot diagram showed the mean change of IOP over time in eyes suffered with RVO-related ME after treatments with anti-VEGF agents and DEX. Follow-up examinations occurred at 1 (a), 2 (b), 3 (c), 4 (d), 5 (e) and 6 months (f) after initiating therapy. Data were presented as mean [95% CI]. IV, inverse variance

Article Snippet: Novartis’ two studies indicated that anti-VEGF agents significantly reduced the CRT compared with DEX implant at 6 months [weighted mean difference: 158.53 μm, 95% confidence interval (CI): (71.09, 245.96), P = 0.0004].

Techniques:

Journal: Indian Journal of Ophthalmology

Article Title: Comparison between Ozurdex and intravitreal anti-vascular endothelial growth factor treatment for retinal vein occlusion–related macular edema: A systematic review and meta-analysis of randomized controlled trials

doi: 10.4103/ijo.IJO_382_19

Figure Lengend Snippet: A forest plot diagram showed one of the adverse events, cataract, in the eyes suffered with RVO-related ME after treatments with anti-VEGF agents and DEX. The follow-up examinations occurred at 6 months, the endpoint of clinical trial. Data were presented as mean [95% CI]. IV, inverse variance

Article Snippet: Novartis’ two studies indicated that anti-VEGF agents significantly reduced the CRT compared with DEX implant at 6 months [weighted mean difference: 158.53 μm, 95% confidence interval (CI): (71.09, 245.96), P = 0.0004].

Techniques:

Journal: Clinical Ophthalmology (Auckland, N.Z.)

Article Title: Analysis of Funding Source and Spin in the Reporting of Studies of Intravitreal Corticosteroid Therapy for Diabetic Macular Edema: A Systematic Review

doi: 10.2147/OPTH.S262085

Figure Lengend Snippet: Summary of Full-Text Study Assessments

Article Snippet: Maturi et al (2018) , 5.6 , 2 , 129 , IVR ± IV DEX Implant , BCVA , No , Yes , COI Present , No , Yes , Genentech, Allergan , -.

Techniques: